Genentech (DNA) traded up marginally after beating expectations.  The company posted $0.61 EPS vs $0.56 estimates and total product sales of $2.053 Billion; revenues were $2.714 Billion versus $2.55 Billion estimates. 

They forecast 2007 EPS at $2.79-2.90, ahead of expectations.  Shares closed down 1.1% on the day on 6.3+ million shares, and shares are up 1% at $84.65 on last look.

Here were quarter sales in the U.S. (in millions):
Rituxan®         $560
Avastin® *        $490
Herceptin®        $322
Tarceva®          $107
Nutropin®         $101
Xolair®           $117
Thrombolytics     $62
Pulmozyme®        $53
Raptiva®          $24
LUCENTIS®         $217

Here was our directional call ahead of the earnings from earlier.

Jon C. Ogg